Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell […]
Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.
In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.
Our lead […]
Melbourne, Australia, 27 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.
This […]
Melbourne, Australia, 6 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune stem cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.
The facility was officially opened by the […]
Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.
Mat’s key […]
In the competitive biotech landscape, groundbreaking science alone isn’t enough. As highlighted in a recent article by Dynamic Business, Cartherics’ strategic appointment of U.S. biotech executive Laurence Nore underscores the critical importance of navigating the complexity of healthcare markets. Laurence emphasises that many promising biotech firms falter not due to flawed science but because they […]
In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]
Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative approach to cell therapy. Unlike traditional cell therapies, Cartherics employs gene-edited natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) from umbilical cord blood.
This approach aims to enhance the immune system’s […]
Melbourne, Australia, 28 May 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications.
As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
